REGULATORY AFFAIRS OUTSOURCING

Similar documents
REGULATORY AFFAIRS OUTSOURCING WHY

CAN QUALITY BE OUTSOURCED? dictated by good business practices. that quality is a product or service: that consistently has zero defects

SUPPLIERS SELECTION AND ASSESSMENT

EXPERT ISE YOU CAN TRUST

Emerging Trends in Regulatory Outsourcing WHITE PAPER.

Who We Are / Services

GMP.. A Journey of 1000 miles starts with 1st Step.Induction.

Your Complete Quality Solution Provider for the Life Science Industry

DIFFERING CMC REQUIREMENTS: US AND EU

Drug Registration in BRICS countries: Opportunities and Challenges. Judith ter Horst 1 November 2018

Outsource or in-house? The evolving role of analytical services in pharmaceutical manufacturing

Overview of global registration of vaccines

Strategic Outsourcing for Success

Revision of the Variations Regulation. Key Principles and Guidelines Development CONTENT

IDMP update: A practical approach to IDMP implementation and the impact of the possible new phasing

Maintenance of Mature and Generic Products

Job Openings at SoliPharma

REGULATORY RESOURCES GROUP. a different approach. a range of services to suit your needs

GxP Auditing, Remediation, and Staff Augmentation

Drug-Device Combination Product Development: INDs for Device Companies

PPTA Regulatory Workshop June 13, 2016

EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL QUESTIONS. and ANSWERS

WHITE PAPER. Overview

Best practice of worldwide product variations regarding planning, conduct and implementation

Marketing Authorisation Routes in the EU

EU Orphan Drug Launch

GxP Auditing, Remediation, and Staff Augmentation

Conditional marketing authorisation

Impact factor: 3.958/ICV: 4.10 ISSN:

Unlocking hidden value within regulatory affairs

Coraggio s Strategic Clarity Framework. clarity focus action. vision mission values reputation position imperatives objectives initiatives

GxP Auditing, Remediation, and Quality System Resourcing

MANAGING MATURE PRODUCT PORTFOLIOS - KEY CHALLENGES AND BENEFITS

Regulatory Affairs, Compliance Assurance, Quality Systems, Remediation Strategy and Support, and Strategic Consulting Services

Connecting the parts Developing an integrated IDMP strategy

Preparing for the withdrawal is therefore not just a matter for EU and national authorities, but also for private parties.

13 October Structured Product Labeling: Four Strategies to Comply with FDA s SPL Mandate

Clinical Trial Supplies. Establishing Firm Grounds for your Trials

Challenges and Opportunities in the Global Regulatory Environment

Di Renzo Regulatory Affairs ROME - MILAN - LONDON

New Frontiers in the Quality of Medicines

Convert Advisor Subscriptions to CSP The Easy Way

OVERVIEW OF DRUG REGISTRATION REQUIREMENTS FOR PHARMACEUTICALS IN EMERGING MARKET

CAREER DEVELOPMENT FOR EXPERIENCED REGULATORY PROFESSIONALS

Table of Contents. Presented by

Launching drug product in Europe Q&A

The 23 rd Autumn Introductory Course:

Need a Security Workforce Management Platform?

Which Regulation Fits Where?

Brexit Guidance for Stakeholders Human and veterinary medicines

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) POSITION PAPER ON COMPLIANCE WITH PHARMACOVIGILANCE REGULATORY OBLIGATIONS

QUESTIONS AND ANSWERS ON MRP & DCP AND EU ENLARGEMENT

ISPE: Pharma Industry Outlook

KINGSMANN CARE GROUP

Methods to Demonstrate a Financial Return on Investment in Product Stewardship

Electronic Regulatory Submission in the EU: Afssaps perspective France

FIVE SECRETS OF GREAT PUBLISHERS

THE PACMP STRATEGY. March 13-16, 2018

Managed IT Services. Eliminating technology pains in small businesses

COMMENTS FROM EUROPABIO GENERAL COMMENTS

Tackling Pharmaceutical Industry s Regulatory Affairs Challenges with Technology WHITE PAPER

T H E P R O P O S A L F O R T H E Y E A R

Cardinal Health Specialty Solutions. Bringing a new drug to life. Regulatory Sciences

Moving from ISO 9001:2008 to ISO 9001:2015 Transition Guide

Q&A - Pharmacovigilance Legislation

Federal agency for medicines and health products

REGULATORY ANALYSIS OF THE VARIATION PROCEDURES OF MEDICINAL PRODUCTS AFTER THE EU ACCESSION OF BULGARIA FOR THE PERIOD

REQUEST FOR PROPOSAL FOR POLICE OPERATIONS STUDY LOWER SAUCON TOWNSHIP

The Future of Pharmaceuticals for Human Use in Europe Cefic Input to the Consultation Process: Deadline for Submission 12/10/2007 Date: 10/10/07

Visit The facts. 4,400 offices. 73 countries and territories, including 12 countries in Asia Pacific

The Science Behind Smart Outsourcing: Four Steps to Success

UBS 2007 Global Life Sciences Conference. September 24, 2007

Preparing for product launch

Public release of clinical information in drug submissions and medical device applications

Post approval change of Japanese registration dossiers and impact on market supply

8 th STAMP expert group meeting

Introduction to CMC Regulatory Affairs

TENDER MANAGEMENT PRACTICES IN THE LIFE SCIENCES INDUSTRY SURVEY RESULTS, REPORT 1: THE TENDER ORGANIZATION BACKGROUND BENCHMARKING STUDY

Regulatory business process services: A strategic enabler

Practice Optimization Package:

Challenges and Keys to Success for an Orphan Drug Product Launch. Evelyn Kelly MPharm MPSI MBS

Moving to the AS9100:2016 series. Transition Guide

Managed IT Services. Eliminating technology pains for small businesses

Life Sciences Courseware. Knowledge. Performance. Impact.

ICH Q12 (Pharmaceutical Product Lifecycle Management): PMDA Perspective

HD-Guidance document Authorisation human medicine under Art. 13 ATP

Innovative Solutions for the Life Sciences

PhlexEview: Transforming Costly Paper Processes into Value Driven Compliance

Planning of Application

Public Assessment Report. Scientific discussion. Human Albumin CSL Behring 5% and 20% solution for infusion. Human albumin DK/H/1508/ /E/002

How to Choose the Right CMO for Your Pharmaceutical Product

3M Drug Delivery Systems. April 26, 2011

Brexit info meeting. 5 February 2018

Focused pharma engineering

Pfizer, Inc., Focus on Six Therapeutic Areas + Biosimilars Global Commercial Organization/Business Units

Effective application of Risk Management techniques to Drug Safety: a pragmatic approach

Moving to the AS/EN 9100:2016 series. Transition Guide

Teva Pharmaceutical Industries Ltd. J.P. Morgan Healthcare Conference. Kåre Schultz President and CEO January 7, 2019

Sec Short title; finding. Sec Authority to assess and use drug fees. Sec Reauthorization; reporting requirements.

Transcription:

REGULATORY AFFAIRS OUTSOURCING WHY SHOULD YOU OUTSOURCE? Regulatory Affairs Unit in a pharmaceutical company is a vital unit that drives the R & D efforts of the company to the market successfully. Today a Regulatory Affairs department is a dynamic business unit which works with a focus to get products to the market with a commercially viable label in the least possible time and expenses. Today the world has become a global village and many companies are in a race to place many new products in the world markets to gain market share and increase earnings. In such a scenario a small delay in gaining market access means huge loss in terms of market share and revenue generated. The key to success for pharmaceutical companies lies in obtaining timely marketing approval from regulators. So to obtain timely marketing approval companies can either strengthen then regulatory department or outsource the same to regulatory affairs consulting firm. With changing global regulatory norms, outsourcing regulatory affairs work seems a more beneficial option both in terms of time and money. Maintaining a large regulatory affairs department can be very expensive and scope of knowledge can be limited to certain aspects. On the other hand a regulatory affairs consultant keeps on updating himself with the current regulation and has vital experience in the field to expedite the approval process. Pag. 1 / 6

TACTICAL VS. STATEGICAL OUTSOURCING The Regulatory Affairs service can be as simple as CTD drawing up and review or as complex as e-submission with detailed consultation on FDA or GMP regulations. Outsourcing basically breaks down into two categories: 1) TACTICAL 2) STRATEGICS The first step in the decision to outsource is determining in which category your needs fall. TACTICAL OUTSOURCING is a short-term solution. The need for this type of outsourcing can result from a fluctuation in a demand of documentation review for e.g. Tactical outsourcing can also give temporary relief of bottleneck situations when a RA department is overwhelmed by large volume or slow output. STRATEGICAL OUTSOURCING, on the other hand, involves a long-term partnership. By utilizing this type of outsourcing, a RA department can reap many long-term benefits, including decreased overhead costs and the ability to advance projects of lower priority. When choosing an out-sourcing RA department it is important to know what types of competence or consultation you require. identifying what services will best suit your needs is a critical step in the decision to outsource. Pag. 2 / 6

WHICH ARE THE KEY FACTORS IN A REGULATORY AFFAIRS PARTNER? EXPERIENCE: Experience in pharmaceutical industry particularly in drug development is an essential for pharmaceutical regulatory consultants. Consultants should have experience in preparation and submission of regulatory documents. CONFIDENTIALITY: A Confidentiality agreement has to be in place to protect your company s proprietary knowledge. A consultant s confidentiality can be evaluated by requesting previous studies and information shared can be used to judge the same. STAFF: A company must have adequate staff to serve ongoing projects without delay. The staff must be highly skilled and trained to carry out regulatory work. Staffing capability can be judged by visiting the consultant s office, professional associations, website information and office locations. COLLABORATIONS: The Company must have access to key technical and scientific resources at their disposal for timely completion which can be achieve by having in house facility or collaboration with other service providers. SYSTEM: Company should have in place standard system to carry out the work effectively. Initial communication with the company will give an impression of how far the company is organized and follows a standard system. TECHNOLOGY: Technology has become a key part for success and timely submission today. With the introduction of ectd it has become important for companies to integrate technology in their companies. Pag. 3 / 6

OUR REGULATORY AFFAIRS SKILLS EFFICIENT REGULATORY STRATEGY MAKES THE DIFFERENCE Our Team works proactively and proposes the regulatory strategy which will bring the product to market on the desired day. Taking into account a number of parameters such as patent situation in EU, data exsclusivity period, markets of interest, comparison of SmPCs in the respective countries, sunset clause and, dossier availability, etc., we propose the most suitable RMS as well as the complete strategy in order to ensure timely product launch and meeting reimbursement and substitution requirements in each country. Our main aim is to take care of our client s timelines, market needs, regulatory cost budget and other special arrangements. E-CTD PREPARATION ectd submissions are increasingly preferred by the European regulatory authorities, which offer either cost or time incentives to the companies that are willing to submit electronically their dossiers. We offer dossier preparation in both CTD or ectd as well as converting paper CTD to fully compliant ectd. Pag. 4 / 6

CTP SYSTEM IS THE RIGHT CHOICE SITE COMPLIANCE & REGULATORY GAP Analysis DMF, CTD, TF compilation and review (all modules) Post marketing applications (Variations and renewals) Regulatory support from development to MA granting and beyond SUBMISSION SUPPORT Marketing authorisation applications National, DCPs and MRPs Regulatory support in FDA procedure ectd Training Software Validation Pag. 5 / 6

A global system, a perfect mechanism, an organic approach. CTP SYSTEM: the solution. PLANNING FOR THE FUTURE Regulatory affairs outsourcing is on a growth worldwide, many large and small companies have adopted this strategy to get a timely approval. Even multinational firms are outsourcing their regulatory work to lessen the pressure on their in house team or to support the same. Outsourcing is "one of the greatest organizational and industry structure shifts of the century." w w w. c t p s y s t e m. c o m i n f o @ c t p s y s t e m. c o m Località Salceto, 91/93 53036 Poggibonsi (Siena) Tel. +39 0577 98481 Via G. Stephenson, 94 20157 Milano Tel. +39 02 49681311 Via Campobello, 7 00040 Pomezia (Roma) Tel. +39 06 9122873 Fax +39 0577 980762 Fax +39 02 49681344 Fax +39 06 9120289 Pag. 6 / 6